Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00006229. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II/III Double Blind Randomized Trial of BMS-275291 vs. Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of paclitaxel and carboplatin with or without BMS-275291 in treating patients who have advanced or metastatic non-small cell lung cancer.
Study identification
- NCT ID
- NCT00006229
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 774 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 3, 2000
- Primary completion
- Dec 9, 2003
- Completion
- Feb 9, 2009
- Last update posted
- Apr 5, 2020
2000 – 2009
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35294-3300 | — |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| Scripps Clinic | La Jolla | California | 92037 | — |
| Central Georgia Hematology Oncology, P.C. | Macon | Georgia | 31201 | — |
| Queen's Medical Center | Honolulu | Hawaii | 96813 | — |
| Carle Cancer Center | Urbana | Illinois | 61801 | — |
| Lahey Clinic - Burlington | Burlington | Massachusetts | 01805 | — |
| Creighton University Cancer Center | Omaha | Nebraska | 68131-2197 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73190 | — |
| Erlanger Health Systems | Chattanooga | Tennessee | 37403 | — |
| Memorial Hospital Cancer Center - Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Williamson Medical Center | Franklin | Tennessee | 37068-1600 | — |
| Jackson-Madison County General Hospital | Jackson | Tennessee | 38301 | — |
| Baptist Regional Cancer Center - Knoxville | Knoxville | Tennessee | 37901 | — |
| Saint Thomas Hospital | Nashville | Tennessee | 37205 | — |
| Meharry Medical College | Nashville | Tennessee | 37208-3599 | — |
| Division of Medical Oncology - Vanderbilt | Nashville | Tennessee | 37232-5536 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00006229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2020 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00006229 live on ClinicalTrials.gov.